Salix price target raised to $53 from $44 at Brean Capital Brean Capital raised its price target on Salix following Q4 results. The firm cited better than expected sales for both Xifan and Relistor as well as increased guidance. Shares are Buy rated.
Salix upgraded to Buy from Neutral at UBS UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.